Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting

André Mesquita (), Carlos Rocha-Castro, Daniela Guimarães, Joana Costa, Joana Soutinho and Tiago Taveira-Gomes
Additional contact information
André Mesquita: USF Sanus Carandá, ACeS Cávado I-Braga, 4715-402 Braga, Portugal
Carlos Rocha-Castro: USF do Minho, ACeS Cávado I-Braga, 4715-402 Braga, Portugal
Daniela Guimarães: USF Dr. Pelaez Carones, ACeS Cávado I-Braga, 4715-402 Braga, Portugal
Joana Costa: USF Gualtar, ACeS Cávado I-Braga, 4710-078 Braga, Portugal
Joana Soutinho: USF MaxiSaúde, ACeS Cávado I-Braga, 4700-036 Braga, Portugal
Tiago Taveira-Gomes: MTG Research and Development Lab, 4200-604 Porto, Portugal

IJERPH, 2022, vol. 19, issue 19, 1-12

Abstract: Helicobacter pylori ( H. pylori ) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended to characterize the prescribed treatments evaluating effectiveness, adverse outcomes and compliance in a real-world setting in a primary care unit. A prospective multicenter observational cohort study was developed in five primary care units of Braga, Portugal. Patients diagnosed with H. pylori infection from August 2021 to January 2022 were included. Data were collected by interview (3 weeks after treatment) and review of medical records. Comparison between two groups of treatment and multivariable analysis was conducted. We estimated 13.4 cases per 1000 adults/year from 185 diagnoses. Therapy with bismuth was the most prescribed (83.8%) with a 96.7% eradication rate. There were no significant differences between treatments. Adverse events were reported in 73.8% of inquiries and female patients were associated with higher reports of nausea ( p = 0.03) and metallic taste ( p = 0.02). Both eradication schemes were effective and secure. The higher rate of adverse outcomes should be validated but it could influence the debate concerning treating all patients, especially in low gastric cancer-prevalence regions.

Keywords: Helicobacter pylori eradication; quadruple therapy with bismuth; effectiveness; compliance; adverse events (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/19/12847/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/19/12847/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:19:p:12847-:d:935644

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().